Pulmonary Hypertension

June 24, 2016June 24, 2016

Reata Announces Positive Interim Data on LARIAT Phase 2 Clinical Trial for PAH

Reata Pharmaceuticals released interim data from its extension Phase 2 LARIAT clinical trial evaluating bardoxolone methyl for the treatment of pulmonary arterial hypertension (PAH). Bardoxolone methyl is an investigational, oral, once-daily antioxidant inflammation modulator ... Read more

June 24, 2016June 24, 2016

Pulmonary Arterial Hypertension Severity Could Be Assessed in Future with a Blood Test

News, Pulmonary Hypertension

Researchers at Johns Hopkins University School of Medicine, in Maryland, revealed that hematoma derived growth factor (HDGF) might be a good biomarker to predict disease severity in pulmonary arterial hypertension (PAH) patients. The findings were recently published ... Read more

June 23, 2016June 23, 2016

SteadyMed and PHA Aim to Inspire Pulmonary Hypertension Patients with PHenomenal Campaign

News, Pulmonary Hypertension

SteadyMed and the Pulmonary Hypertension Association (PHA) recently launched the PHenomenal campaign, an initiative to offer people with pulmonary hypertension (PH) and their families a platform to share photos and videos of ... Read more

June 22, 2016June 22, 2016

Riociguat is Safe and Effective Way of Treating CTEPH Treatment Over Long Term, Review Finds

News, Pulmonary Hypertension

Results from the ongoing Phase 3 study known as CHEST-2 support the long-term use of riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH). The findings are detailed in the study, “Predictors ... Read more

June 22, 2016June 22, 2016

INOpulse Devices for PAH Disorders Evaluated in Clinical Trials

COPD, Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

Bellerophon Therapeutics recently enrolled the first participants in the Phase 3 INOvation-1 clinical trial intended to test the efficiency and safety of INOpulse for the treatment of pulmonary arterial hypertension (PAH). ... Read more

June 17, 2016June 17, 2016

Uptravi (Selexipag) Now Available for PAH Patients in Germany

News, Pulmonary Hypertension

Actelion announced that one of its lead products, Uptravi (selexipag), designed for the treatment of pulmonary arterial hypertension (PAH), has become commercially available in Germany. The drug was granted market authorization by the European ... Read more

June 9, 2016June 9, 2016

Crucial Molecule May Lead to Novel Therapies for Pulmonary Arterial Hypertension

News, Pulmonary Hypertension

In a recent study published in the The Journal of Clinical Investigation, researchers reported to have identified a crucial factor for the development of pulmonary arterial hypertension (PAH). The discovery identified a ... Read more

June 7, 2016June 7, 2016

Researchers Study Role of Vascular Stiffening in Pulmonary Arterial Hypertension

News, Pulmonary Hypertension

A recent study suggested that vascular stiffening induces the development of pulmonary arterial hypertension (PAH). The findings were described in the article, “Distal vessel stiffening in an early and pivotal mechanobiological ... Read more

June 6, 2016June 6, 2016

Pulmonary Arterial Hypertension Candidate by Galectin Shows Positive Results

Pulmonary Hypertension

Galectin Therapeutics, Inc. recently reported that GR-MD-02, the company’s lead candidate galectin-3 (gal-3) inhibitor, has demonstrated a positive effect on vascular remodeling in mouse models of pulmonary arterial hypertension (PAH). The ... Read more

May 31, 2016May 31, 2016

Raising Pulmonary Hypertension Awareness at ‘Breathless on Broadway’ Event

News, Pulmonary Hypertension

The 2nd annual “Breathless on Broadway,” an event devoted to raise awareness about pulmonary hypertension (PH), will take place this year on June 6 at Sardi’s Restaurant in NYC. The ... Read more